Bayer and Iambic partner on AI-driven small molecule drug discovery
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Bayer and Iambic Collaborate to Advance Drug Discovery with AI
June 22, 2026 8:00 AM EDTCollaboration focuses on small molecule discovery Bayer to leverage Iambics AI platform to address hard-to-drug targets Collaboration will strengthen Bayers research and development portfolio by harnessing AI to accelerate drug discovery
BERLIN & SAN DIEGO--(BUSINESS WIRE)-- Bayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambics AI-driven platform. The collaboration is focused on small molecule discovery.
The collaboration will leverage Iambics AI-driven drug discovery... More



